Table 1.
Patient Population and Disease Characteristics of New Biologics Starts in the Corrona Psoriasis Registry, 2018
| Variables | Pacific | Mountain/West North Central | West South Central | East North Central | East South Central | Northeast | South Atlantic | Total | P-Value |
|---|---|---|---|---|---|---|---|---|---|
| Total, n (%) | N = 100 | N = 94 | N = 48 | N = 56 | N = 106 | N = 217 | N = 96 | N = 717 | |
| Age, mean (SD) | 51.9 (15.5) | 49.2 (14.2) | 52.6 (14.4) | 50.2 (16.3) | 50.3 (13.0) | 49.8 (15.4) | 49.9 (14.7) | 50.3 (14.8) | 0.8091 |
| Female sex, n (%) | 36 (36.0) | 39 (41.5) | 24 (50.0) | 23 (41.1) | 63 (59.4) | 105 (48.4) | 50 (52.1) | 340 (47.4) | 0.0232 |
| Race, n (%) | <0.0012 | ||||||||
| White | 31 (31.0) | 84 (89.4) | 39 (81.2) | 52 (92.9) | 102 (96.2) | 180 (82.9) | 81 (84.4) | 569 (79.4) | |
| Other3 | 69 (69.0) | 10 (10.6) | 9 (18.8) | 4 (7.1) | 4 (3.8) | 37 (17.1) | 15 (15.6) | 148 (20.6) | |
| Insurance, n (%)4 | |||||||||
| Private | 45 (45.0) | 65 (69.1) | 35 (72.9) | 46 (82.1) | 71 (67.0) | 173 (79.7) | 78 (81.2) | 513 (71.5) | <0.0012 |
| Medicare | 24 (24.0) | 18 (19.1) | 11 (22.9) | 11 (19.6) | 21 (19.8) | 29 (13.4) | 11 (11.5) | 125 (17.4) | 0.1392 |
| Medicaid | 43 (43.0) | 12 (12.8) | 2 (4.2) | 5 (8.9) | 26 (24.5) | 25 (11.5) | 4 (4.2) | 117 (16.3) | <0.0012 |
| No insurance | 4 (4.0) | 4 (4.3) | 3 (6.2) | 2 (3.6) | 0 (0.0) | 1 (0.5) | 5 (5.2) | 19 (2.6) | 0.0352 |
| BMI, n (%) | <0.0012 | ||||||||
| <25 (underweight/normal) | 35 (35.0) | 13 (13.8) | 6 (12.8) | 7 (12.5) | 17 (16.5) | 57 (26.3) | 22 (23.2) | 157 (22.1) | |
| 25–30 (overweight) | 35 (35.0) | 26 (27.7) | 13 (27.7) | 16 (28.6) | 23 (22.3) | 48 (22.1) | 31 (32.6) | 192 (27.0) | |
| >30 (obese) | 30 (30.0) | 55 (58.5) | 28 (59.6) | 33 (58.9) | 63 (61.2) | 112 (51.6) | 42 (44.2) | 363 (51.0) | |
| Smoking history, n (%) | n = 214 | n = 56 | n = 94 | n = 94 | n = 106 | n = 47 | n = 98 | n = 709 | 0.0012 |
| Never | 99 (46.3) | 21 (37.5) | 42 (44.7) | 59 (62.8) | 45 (42.5) | 26 (55.3) | 61 (62.2) | 353 (49.8) | |
| Former | 88 (41.1) | 23 (41.1) | 27 (28.7) | 22 (23.4) | 30 (28.3) | 16 (34.0) | 16 (16.3) | 222 (31.3) | |
| Current | 27 (12.6) | 12 (21.4) | 25 (26.6) | 13 (13.8) | 31 (29.2) | 5 (10.6) | 21 (21.4) | 134 (18.9) | |
| Current alcohol use, n (%) | n = 217 | n = 56 | n = 94 | n = 96 | n = 106 | n = 48 | n = 100 | n = 717 | 0.0012 |
| None and/or occasional | 114 (52.5) | 36 (64.3) | 40 (42.6) | 59 (61.5) | 81 (76.4) | 27 (56.2) | 78 (78.0) | 435 (60.7) | |
| 1–3 drinks per week | 25 (11.5) | 6 (10.7) | 9 (9.6) | 7 (7.3) | 8 (7.5) | 5 (10.4) | 7 (7.0) | 67 (9.3) | |
| 4–6 drinks per week | 36 (16.6) | 4 (7.1) | 16 (17.0) | 15 (15.6) | 6 (5.7) | 4 (8.3) | 5 (5.0) | 86 (12.0) | |
| 1–2 drinks per day | 29 (13.4) | 4 (7.1) | 16 (17.0) | 8 (8.3) | 4 (3.8) | 4 (8.3) | 8 (8.0) | 73 (10.2) | |
| ≥3 drinks per day | 13 (6.0) | 6 (10.7) | 13 (13.8) | 7 (7.3) | 7 (6.6) | 8 (16.7) | 2 (2.0) | 56 (7.8) | |
| Duration of Psoriasis in years, median (Q1, Q3) | 9.0 (4.0, 18.0) | 13.0 (5.0, 23.8) | 6.5 (2.8, 16.2) | 13.0 (5.0, 25.5) | 7.5 (3.0, 17.0) | 13.0 (6.0, 24.0) | 10.0 (3.5, 25.5) | 11.0 (4.0, 21.2) | <0.0015 |
| Age at onset of psoriasis in years, median (Q1, Q3) | 42.0 (25.8, 53.0) | 33.0 (21.0, 45.8) | 39.5 (25.0, 52.5) | 29.0 (18.0, 51.2) | 41.0 (25.2, 51.8) | 33.0 (19.0, 45.0) | 32.0 (22.0, 47.5) | 35.0 (21.0, 50.0) | <0.0015 |
| BSA—categorical, n (%) | 0.0062 | ||||||||
| Mild (0–3) | 6 (6.0) | 24 (25.5) | 5 (10.4) | 11 (19.6) | 20 (18.9) | 27 (12.4) | 11 (11.5) | 104 (14.5) | |
| Moderate (3–10) | 58 (58.0) | 45 (47.9) | 23 (47.9) | 25 (44.6) | 48 (45.3) | 118 (54.4) | 44 (45.8) | 361 (50.3) | |
| Severe (10–20) | 19 (19.0) | 12 (12.8) | 8 (16.7) | 6 (10.7) | 9 (8.5) | 33 (15.2) | 22 (22.9) | 109 (15.2) | |
| Very severe (>20) | 17 (17.0) | 13 (13.8) | 12 (25.0) | 14 (25.0) | 29 (27.4) | 39 (18.0) | 19 (19.8) | 143 (19.9) | |
| Previous biologic Therapies, n (%) | 0.0162 | ||||||||
| Biologic naive | 37 (37.0) | 39 (41.5) | 18 (37.5) | 18 (32.1) | 35 (33.0) | 88 (40.6) | 42 (43.8) | 277 (38.6) | |
| 1 previous biologic | 36 (36.0) | 20 (21.3) | 15 (31.2) | 20 (35.7) | 18 (17.0) | 46 (21.2) | 20 (20.8) | 175 (24.4) | |
| 2+ previous biologics | 27 (27.0) | 35 (37.2) | 15 (31.2) | 18 (32.1) | 53 (50.0) | 83 (38.2) | 34 (35.4) | 265 (37.0) | |
| PASI, median (Q1, Q3) | 7.2 (4.4, 13.2) | 5.4 (2.4, 9.8) | 5.6 (4.0, 10.7) | 4.3 (2.1, 7.4) | 3.7 (1.9, 7.2) | 7.2 (3.2, 11.4) | 5.7 (2.8, 10.7) | 5.7 (2.8, 10.8) | <0.0015 |
| IGA, n (%) | 0.0802 | ||||||||
| Clear | 1 (1.0) | 2 (2.1) | 1 (2.1) | 6 (10.7) | 4 (3.8) | 7 (3.2) | 4 (4.2) | 25 (3.5) | |
| Almost clear | 2 (2.0) | 11 (11.7) | 3 (6.2) | 3 (5.4) | 0 (0.0) | 14 (6.5) | 4 (4.2) | 37 (5.2) | |
| Mild | 16 (16.0) | 18 (19.1) | 8 (16.7) | 9 (16.1) | 15 (14.2) | 39 (18.0) | 14 (14.6) | 119 (16.6) | |
| Moderate | 64 (64.0) | 46 (48.9) | 28 (58.3) | 33 (58.9) | 70 (66.0) | 124 (57.1) | 56 (58.3) | 421 (58.7) | |
| Severe | 17 (17.0) | 17 (18.1) | 8 (16.7) | 5 (8.9) | 17 (16.0) | 33 (15.2) | 18 (18.8) | 115 (16.0) | |
| Comorbid disease | |||||||||
| Cancer | 2 (2.0) | 9 (9.6) | 3 (6.2) | 1 (1.8) | 8 (7.5) | 21 (9.7) | 8 (8.3) | 52 (7.3) | 0.1482 |
| Cardiovascular disease | 7 (7.0) | 6 (6.4) | 8 (16.7) | 1 (1.8) | 7 (6.6) | 17 (7.8) | 7 (7.3) | 53 (7.4) | 0.1782 |
| Hypertension | 40 (40.0) | 33 (35.1) | 23 (47.9) | 19 (33.9) | 46 (43.4) | 81 (37.3) | 33 (34.4) | 275 (38.4) | 0.5782 |
| Hyperlipidemia | 32 (32.0) | 15 (16.0) | 13 (27.1) | 13 (23.2) | 38 (35.8) | 65 (30.0) | 28 (29.2) | 204 (28.5) | 0.0682 |
| Diabetes mellitus | 19 (19.0) | 12 (12.8) | 8 (16.7) | 4 (7.1) | 25 (23.6) | 36 (16.6) | 11 (11.5) | 115 (16.0) | 0.0972 |
Abbreviations: BMI, body mass index; IGA, Investigator’s Global Assessment; Q, quartile.
1
P-value from ANOVA.
2
P-value from chi-square test.
3
Race category Other includes African American, Asian, Other; these were collapsed owing to small cell counts (n < 5).
4
Not mutually exclusive.
5
P-value from Kruskal‒Wallis test.